In the present study, we investigated whether Neuroaspis PLP10™, a well-designed intervention, rich in omega-3 (n-3) and omega-6 (n-6) polyunsaturated fatty acids (PUFAs) with specific antioxidant vitamins, may exert positive action in the improvement of Parkinson’s disease symptoms and perhaps delay the progression of the disease when used as an adjuvant to the conventional treatment. Forty patients were randomized 1:1 to receive either 20 ml dose, once daily, of control (pure virgin olive oil) or Neuroaspis PLP 10™, a formula containing a mixture of omega-3 (810 mg Eicosapentaenoic acid and 4140 mg Docosahexaenoic acid) and omega-6 fatty acids (1800 mg gamma-Linolenic acid and 3150 mg Linoleic acid) (1:1 w/w), with 0.6 mg vitamin A, vitamin E (22 mg) plus pure gamma (γ)-tocopherol (760 mg), for a total of 30 months in a randomized double-blind, placebo-controlled trial. Participants completed assessments based on the Hoehn and Yahr Staging Scale of Parkinson’s Disease (HY scale) and the Unified Parkinson's Disease Rating Scale (UPDRS) III.

Overall, for this small sample size clinical trial, Neuroaspis PLP10™ supplementation as an adjuvant treatment for 30 months in PD patients significantly delayed disease progression according to UPDRS (p ≤ 0.05) Vs placebo.

在本研究中，我们调查了 Neuroaspis PLP10™，一种精心设计的干预措施，富含 omega-3 (n-3) 和 omega-6 (n-6) 多不饱和脂肪酸 (PUFA) 以及特定的抗氧化维生素，是否可以发挥当用作常规治疗的辅助剂时，对改善帕金森病症状有积极作用，并可能延缓疾病的进展。40 名患者以 1:1 的比例随机接受 20 毫升剂量的对照（纯初榨橄榄油）或 Neuroaspis PLP 10™，这是一种含有 omega-3（810 毫克二十碳五烯酸和 4140 毫克二十二碳六烯酸）混合物的配方) 和 omega-6 脂肪酸（1800 毫克 γ-亚麻酸和 3150 毫克亚油酸）（1:1 w/w），含 0.6 毫克维生素 A、维生素 E（22 毫克）和纯 γ（γ）-生育酚（ 760 毫克），随机双盲共 30 个月，安慰剂对照试验。参与者完成了基于帕金森病 Hoehn 和 Yahr 分期量表 (HY 量表) 和统一帕金森病评定量表 (UPDRS) III 的评估。

总体而言，对于这个小样本量的临床试验，根据 UPDRS (p ≤ 0.05) 与安慰剂相比，Neuroaspis PLP10™ 补充剂作为 PD 患者 30 个月的辅助治疗显着延缓了疾病进展。